English
Polski
Español
українська
The 3 most important recent advances in the management of venous thrombosis
Dr James Douketis from McMaster University shares his views on the 3 most important recent advances in the management of venous thrombosis.
2021-10-14
Dr James Douketis from McMaster University shares his views on the 3 most important recent advances in the management of venous thrombosis.
Dr Adam Torbicki, professor of medicine at Center of Postgraduate Medical Education in Warsaw, Poland, presents the 3 most recent advances in treating pulmonary embolism.
Should we treat patients with suspected subsegmental pulmonary embolism seen on computed tomography (CT)?
Preliminary results of a survey among physicians show that many still consider the D-dimer test as the first choice to confirm an episode of venous thromboembolism (VTE). Could you comment on the value of the pretest probability evaluation before choosing an appropriate test?
What is the use of low-dose direct oral anticoagulants (DOACs) in venous thromboembolism (VTE)?
How to properly evaluate bleeding risk before starting anticoagulation?
Should we switch patients treated with warfarin to direct oral anticoagulants (DOACs)? Who would benefit, and who would not?
What should be the treatment of cancer-associated thrombosis?
